The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today.
Dimethyl fumarate was approved in March 2013 by the US Food and Drug Administration (FDA), and has approvals as well in Canada and Australia. As of September 2013, approximately 35,000 patients worldwide were being treated with this oral agent, the company estimates.
The company plans to introduce dimethyl fumarate in initial European Union (EU) countries "in the coming weeks," Biogen Idec notes in a statement.
Nessun commento:
Posta un commento